Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Recent advancers list up 33% and down 60%, eeek .
Nasdaq 100 list up 37% and down 60% very bearish.
OTC BB Top 100 27% up and 53% down. Very bearish day.
OTC Picks the only pick list on the upside today, baddddddd day for the recent gainers.
MDG List Method 3 only method of 4 advancing today. Booooooo.
Tough day so far, it looks like.
JRSE moving up nicely.... over 23% improvement today.
Not too many in the positive now we'll check again after 10 am
DGKO up over 20% so far.
SURE isnt over yet. up 13% from yesterday.
New MDG Method 4 ( volume building, fast gaining pps stocks in the one week charts ).
NYMX
SURE
HPNN
DGKO
CNTL
New MDG Method 4 ( volume building, fast gaining pps stocks in the one week charts ).
NYMX
SURE
HPNN
DGKO
CNTL
HOT HOT HOT New Prospects Charts ( they are so good had to post them )....
Yup I hope the news today moves it, I have some really juicy ones in my new prospects list post, Need to check them for news and building volume but I will chart all 18 of them and watch the flowwwww.
Interesting New Prospects that have recently gone 2 to 4X.
ACHM
CDTN
CNTL
DGKO
DHPI
EDXC
GPGI
HDHL
HPNN
JRSE
MLRI
NYMX
ONTV
PGPU
SPZI
SURE
WDCV
WMBN
Just added SPRX to my MDG list yesterday, its looks like a great one.
(OTC Bulletin Board: CWLC)
China Wireless Announces Additional Contract With China's Top Brokerage Firm,Bo-hai Securities Company Ltd.
DENVER, March 21 /PRNewswire-FirstCall/ -- China Wireless Communications,
Inc., (OTC Bulletin Board: CWLC), is pleased to announce that it has signed an
additional contract with the Tianjin Bo-hai Securities Company Ltd. Tianjin Create Co., a systems integration company and subsidiary of China Wireless Communications, has signed an additional contract to provide computerhardware and software, maintenance and technical support for Bo-hai Securities Company Ltd.
Bo-hai Securities Company Ltd. was founded in 1986, has registered capital
of $280M USD and is China's top securities company. Bo-hai's operations
consist of 4 affiliate institutions which manage securities for 30 major
investment companies. The company employs 1000 staff with its corporate
headquarters in Tianjin. There are 2 administrative branches, one in Beijing
and one in Shanghai, and 31 additional sales offices throughout China.
Frank Li, President of Create Co. commented, "We are excited about
continuing our already strong relationship with Bo-hai Securities Company Ltd.
This existing relationship will allow us to build industry contacts and
broaden our business opportunities in the rapidly growing business sectors in
China."
CONTACT:
Michael Bowden
Chief Operations Officer
China Wireless Communications, Inc.
info@chinawirelesscommunications.com
www.chinawirelesscommunications.com
303.277.9968 Office
SOURCE China Wireless Communications, Inc.
Michael Bowden, Chief Operations Officer of China Wireless Communications,
Inc., +1-303-277-9968, info@chinawirelesscommunications.com
21Mar06 12:00 GMT
Symbols:
de;CZW us;CWLC
Source PRN PR Newswire
(OTCBB:ONEI) Oneida Receives Approval of First-Day Motions
ONEIDA, N.Y., March 20, 2006 (PRIMEZONE) -- Oneida Ltd. (OTCBB:ONEI) today
marked further progress in its recapitalization plan, announcing that it has
obtained relief under its "first day motions" relating to employee, financing
and other operational matters from the U.S. Bankruptcy Court for the Southern
District of New York.
The relief granted by the Court includes the authority to continue payment of
employee salaries, wages and benefits and the interim authority to continue
performance of its obligations to customers, suppliers and business partners. In
addition, Oneida received interim approval of the previously announced $40
million revolving credit facility arranged with JP Morgan Chase that will
provide financing for the company during these proceedings.
Terry G. Westbrook, Oneida's President and CEO, said: "Our operations have
continued to run smoothly since we announced our recapitalization plan just over
a week ago, and our customers and suppliers have been very supportive of our
recapitalization effort. We are pleased to have received Court approval for
these motions, which enable us to operate our business as usual."
About Oneida
Incorporated in 1880, Oneida Ltd. is one of the world's largest sourcing and
distribution companies for stainless steel and silverplated flatware for both
the consumer and foodservice industries. It is also the largest supplier of
dinnerware to the foodservice industry in North America. Additional information
about Oneida can be found at www.oneida.com.
Note on Forward-Looking Statements
This press release includes forward-looking information and statements. These
statements are based on current expectations, estimates and projections. These
expectations, estimates and projections are generally identifiable by statements
containing words such as "expects," "believes," "estimates," "targets," "plans"
or similar expressions. However, there are many risks and uncertainties, many of
which are beyond our control, that could cause our actual results to differ
materially from the forward-looking information and statements made in this
press release. For further information regarding risks and uncertainties
associated with Oneida's business, please refer to the "Management's Discussion
and Analysis of Financial Condition and Results of Operations" and "Risk
Factors" sections of Oneida's SEC filings, including, but not limited to, its
annual report on Form 10-K and quarterly reports on Form 10-Q.
-0-
CONTACT: Gavin Anderson & Company
Richard Mahony
212-515-1960
20Mar06 22:11 GMT
Symbols:
us;ONEDP us;ONEI
Source PZM PrimeZone Media
(OTCBB:GTEC) Genesis Equity Partners Acquires Interest in Chinese Pharmaceutical Company
BOCA RATON, Fla., March 21, 2006 (PRIMEZONE) -- Genesis Technology Group, Inc.
(OTCBB:GTEC) announced that its subsidiary, Genesis Equity Partners, LLC, signed
a contract with the Liang Fang Pharmaceuticals, Ltd., one of China's most
respected and innovative drug development, medical device, and retail drug store
enterprises.
Liang Fang reportedly grossed over $15.8 million in revenues, almost $ 2.6
million in net profits in 2005, plus net assets exceeding $ 7.5 million. For the
past three fiscal years combined, Liang Fang's revenues exceeded a total of $
31.2 million. Based on its first quarter sales for 2006, the Beijing-based
manufacturer, which also has 10 retail outlets, forecasts an increase to over
$20 million in revenues this year. Genesis Equity Partners will receive a
significant equity position in Liang Fang and ongoing consulting fees for
coordination and oversight of its U.S. business activities.
Among Liang Fang's best selling products, Valsartan Capsules are a medicine for
primary hypertension or high blood pressure. Valsartan first came to market in
America in 1996, known as Diovan. The Novartis AG version of the Diovan product
generated almost 17 percent of that company's 2004 revenues from branded
pharmaceuticals. Novartis predicted the drug might be its first to generate
annual revenues of more than $5 billion.
Dr. Liu Zhongyi, CEO of Liang Fang, commented: "In July 2001, the National Drug
Administration authorized Liang Fang for the production of Valsartan. With
increased production and marketing, we believe that it should dominate the
Chinese market, where over nine percent of the population suffers from high
blood pressure.
"Valsartan is just one example of the important and successful array of drugs
that Liang Fang has acquired or developed and marketed over the years. Liang
Fang intends to become a global brand, although the market in China is large
enough to sustain our growth rate at over 40% annually. We realize that Western
marketing is often the key to such success, and we intend to capitalize on
Genesis's expertise and network in China, Latin America, and the United States.
"We selected Genesis because of its long history of success and expertise in
China. We carefully studied its GEP merger and acquisition program, and believe
that Liang Fang can flourish globally. In our evaluation, we also reviewed the
performance of another Genesis Chinese client, SunWin Neutraceuticals
(OTCBB:SUWN), and we are confident that Liang Fang could exceed its success, as
a U.S. publicly traded company," concluded Dr. Liu.
Dr. Shaohua Tan, the Genesis Director who negotiated the Liang Fang contract,
added: "We are enthused to add Liang Fang to the list of GEP clients. This
month, Messrs. Wolfson and Clinton joined me in inspecting the world-class Liang
Fang manufacturing plant and two of its Beijing retail stores. The Company's
management, facilities and obvious growth potential impressed us immensely.
"Last month, we announced that Gold Horse International became the newest member
of our innovative merger and acquisition program. Its market sector,
construction and real estate development, ranks among the most active in China.
Now, with Liang Fang, we are entering the health care and pharmaceutical arena,
perhaps the fastest growing industry worldwide."
Annual Shareholders Meeting scheduled on Friday, May 19, 2006, at 1 o'clock P.M.
at the China World Hotel in Beijing, China, located at No. 1 Jianguomenwai
Avenue; telephone (8610) 6505-2266, facsimile (8610) 6505-0828, email
cwh@shangri-la.com and website http://www.shangri-la.com.
About Liang Fang Pharmaceuticals, Limited
Liang Fang Pharmaceuticals, Ltd. is a large comprehensive enterprise which deals
in an integration of the production, trade and retailing of pharmaceuticals. It
possesses the most advanced pharmaceutical-making equipment now in China,
workshops authenticated by the National GMP, a number of first-rate medicines
and other types of medicines produced solely in this corporation, and a large
group of high-tech personnel. Liang Fang covers a business and office area of
2,000 square meters and a storehouse of 1,000 square meters. Altogether there
are four organs attached to this corporation handling respectively the
scientific research on new medicine, the production, wholesale and retail of
medicine.
About Genesis Technology Group, Inc.
Genesis Technology Group, Inc. is a business development firm that fosters
bilateral commerce between Western and Chinese companies. Genesis has created
successful profit centers in product development, manufacturing, distribution,
joint ventures and operational services. The Company has offices in the United
States and China. A 75% owned subsidiary of Genesis, Genesis Equity Capital, LLC
assists Chinese and Western companies in formulating strategies to increase
equity value, while targeting Western stock exchanges as a source of capital and
shareholder support. The core strength of GEP management is creating a first
rate plan to create investor awareness and bring in long-term individual and
institutional investors. GEP should create liquidity in the stock and gain
investor awareness by using tested channels of communications by cogently
articulating the companies' stories. GEP has built successful channels with
expertise in screening and selecting Chinese companies that possess solid
business histories and professional management, and North American public
companies and shells that possess a shareholder base and a history of auditing
and filing, as required by the U.S. Securities & Exchange Commission. For more
information, visit www.genesis-technology.net.
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking
statements." Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future results,
performance or achievements, and may contain the words "estimate," "project,"
"intend," "forecast," "anticipate," "plan," "planning," "expect," "believe,"
"will likely," "should," "could," "would," "may" or words or expressions of
similar meaning. Such statements are not guarantees of future performance and
are subject to risks and uncertainties that could cause the company's actual
results and financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to grow its
business. Actual results may differ materially from the results predicted and
reported results should not be considered as an indication of future
performance. The potential risks and uncertainties include, among others, the
Company's limited operating history, the limited financial resources, domestic
or global economic conditions -- especially those relating to China, activities
of competitors and the presence of new or additional competition, and changes in
Federal or State laws, restrictions and regulations on doing business in a
foreign country, in particular China, and conditions of equity markets. More
information about the potential factors that could affect the Company's business
and financial results is included in the Company's filings, available via the
United States Securities and Exchange Commission.
-0-
CONTACT: Genesis Technology Group, Inc.
Kenneth Clinton
(561) 988-9880
21Mar06 11:30 GMT
Symbols:
us;GTEC
Source PZM PrimeZone Media
Categories:
MST/R/G7 MST/R/NME MST/R/US TGT/BGN
(OTCBB:SEHO)Sense Holdings Spotlights Next-Generation Biometric Security Solution for Ports and Vessels in Online Audio Interview; CEO Reviews Company's Proprietary Advanced Biometric Security Solution for Advanced Port Security
FORT LAUDERDALE, Fla.--(Business Wire)--March 21, 2006--
Sense Holdings, Inc. (OTCBB:SEHO) (FWB:OUP), a developer
of next-generation biometric and explosive detection security
technologies for government and commercial security markets, announced today the availability of a new audio interview with Company CEO Dore Perler, who discusses key elements of the Company's new market-ready biometrics-based platform technology designed to provide advanced security for the cruise vessel and maritime cargo shipping industries.
The product line, called the CheckPrint Cruisetracker Vessel
Access System (CPVAS), was designed to fill a critical gap in homeland
and port operations security in the maritime cruise and cargo
industries. In the interview, Mr. Perler notes that CPVAS was created
to be a flexible, adaptable application platform that can be easily
customized for diverse job-site access needs and security
requirements.
"The products and technology we're developing at Sense Holdings
are all strategically targeted to address some of the fastest-growing
areas of the Homeland Security marketplace," said Mr. Perler. "Our
major new port security solution, the CheckPrint Cruisetracker Vessel
Access System, has been introduced as vulnerabilities in US port
security have become an increasingly serious focus of government and
commercial concern."
The CPVAS products will be marketed to the major cargo and cruise
line companies in the maritime shipping industry. CPVAS is a real-time
access control security product. The proprietary solution integrates
photographic and fingerprinting identification technologies with
computer database solutions to enable vessel personnel or other
security personnel to track individuals moving through the ports.
To hear the full streaming audio interview free of charge, please
visit: http://www.trilogy-capital.com/tcp/sense/interview.html.
About Sense Holdings, Inc.
Sense Holdings is a developer of next-generation biometric
identification systems, and nanotechnology-based micro-sensor
technologies for government, military and commercial security
marketplaces. The Company's wholly-owned subsidiary, Sense
Technologies, deploys proprietary biometric technology based on
advanced fingerprint technology and biometric integration to create a
range of solutions for prisoner identification, time and attendance,
access control applications and other markets. Sense's major customers
include the U.S. Army, the U.S. Department of Corrections, American
Airlines and others. A second wholly-owned subsidiary, MSTI, is an
emerging nanotechnology-based explosives detection technology
development division developing a pipeline of advanced bomb detection
technologies, including a prototype handheld explosive detection wand
device for Homeland Security applications in airports and other
security checkpoints. This hand-held detection alternative is designed
to be a cost-effective solution with extremely high detection
sensitivity and real-time operability. Currently, a proof-of-principle
prototype is undergoing further research and development at the U.S.
Oak Ridge National Laboratory. For investor-specific information about
Sense Holdings, including recent share price data and news
announcements, please visit http://www.trilogy-capital.com/tcp/sense.
To view or download an Investor Fact Sheet about the Company, please
visit http://www.trilogy-capital.com/tcp/sense/factsheet.html. Sense
is also listed on the Frankfurt Stock Exchange under the ticker
symbol, OUP. For other information, please visit
http://www.senseme.com.
Cautionary Statement
This presentation includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could cause
actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such differences
include, but are not limited to, continued acceptance of the Company's
products and services in the marketplace, the ability of the Company
to develop effective new products and receive governmental approvals
of such products, competitive factors, dependence upon third-party
vendors, and other risks detailed in the Company's filings with the
U.S. Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release.
Sense Holdings, Inc.
Dore Perler, 954-726-1422 x 101
dore@senseme.com
or
Financial Communications:
Trilogy Capital Partners
Paul Karon, 800-592-6067
paul@trilogy-capital.com
Copyright Business Wire 2006
21Mar06 08:30 GMT
Symbols:
us;SEHO
Source BW Business Wire
(OTCBB:SEVI), Next Hire, Inc. Announces Revenue from Operations Exceeds $100,000 for December,...
HOUSTON--(Business Wire)--March 21, 2006--
Systems Evolution, Inc. (OTCBB:SEVI), a leading
integrator of Microsoft tools and provider of business consulting services, announced today that its permanent placement division has achieved over $100,000 in revenue per month from operations in December, January and February of 2006.
"This performance is directly attributable to the excellent system Next Hire has established for permanent placement of high-quality candidates in the Infrastructure, and Oil and Gas industries. We congratulate the Next Hire team for exceeding our plan goals for 2006," stated Mr. Robert Rhodes, CEO.
Systems Evolution, Inc.
Mike Campbell, 713-979-1600 ext. 108
investor.relations@systemsevolution.com
Copyright Business Wire 2006
21Mar06 11:28 GMT
Symbols:
us;SEVI
Source BW Business Wire
(OTCBB:WWAT), WorldWater & Power Corp. to Introduce New Mobile Solar Power Unit to Emergency Responders at National Hurricane Conference
PENNINGTON, N.J., March 21, 2006 (PRIMEZONE) -- WorldWater & Power Corp.
developer and marketer of proprietary high-power solar systems,
today announced that it will debut the company's new MobileMaxPure(tm) solar
power unit at the 28th Annual National hurricane Conference to be held in
Orlando, Florida, April 10 through 14.
The MobilMaxPure(tm) critical response unit can be towed into a disaster area by
pickup truck or SUV and immediately provide emergency responders and victims
with the essential services of power generation, water purification and
satellite communications. With the flip of a switch, 15 solar panels
automatically unfold to create a 12x18 foot photovoltaic array that generates
electricity. A bank of high-capacity batteries power the panel deployment and
store electricity for emergency night operations.
Quentin Kelly, Chairman of WorldWater & Power, noted, "MobileMax(tm) has already
proven its value in post-Katrina Waveland, Mississippi - where it is turning
contaminated water into clean drinking water for 5,000 to 10,000 residents every
day. The new MobileMaxPure is our second-generation device, incorporating
everything required by emergency responders. During many disasters, reliable
communications is one of the major problems faced in coordinating relief
efforts. MobileMaxPure(tm) has solved that problem with on-board
satellite-based, wireless voice and data telecommunications, and the power to
operate it under the most severe field conditions. MobileMaxPure(tm) can rapidly
go wherever needed and make the critical difference for people coping with
disasters."
MobileMaxPure(tm) can pump and purify up to 30,000 gallons of water a day,
meeting World Health Organization requirements for drinking water while avoiding
the typical logistical issues associated with trucking in bottled water, as
experienced along the Gulf coast after Katrina. MobileMaxPure(tm) pumps from
streams, ponds, lakes, or from contaminated public water systems, as is often
the case after hurricanes; the water is purified through a three-stage
filtration process using UV purification. At night, solar-generated electricity
stored in the battery array can feed an available 5 horsepower generator to
provide lighting and support other emergency operations.
About WorldWater & Power Corp.
WorldWater & Power Corporation is a full-service, international solar electric
engineering and water management company with unique, high-powered and patented
solar technology that provides solutions to a broad spectrum of the world's
electricity and water supply problems. For more information about WorldWater &
Power Corp., visit the website at www.worldwater.com.
The WorldWater & Power Corporation logo is available at:
http://www.primezone.com/newsroom/prs/?pkgid=1629
-0-
CONTACT: WorldWater & Power Corp.
Jessie Sullivan
(609) 818-0700 X20
JSullivan@worldwater.com
Press Contact:
Mike Breslin Productions LLC
Mike Breslin
(201) 652-1287
mbrez@aol.com
Investor Contact:
Lippert/Heilshorn & Associates, Inc.
Jody Burfening / Chris Witty
(212) 838-3777
cwitty@lhai.com
21Mar06 12:03 GMT
Symbols:
de;WWM us;WWAT
Source PZM PrimeZone Media
Categories:
(Nasdaq: SNSS) Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Small Cell...
SOUTH SAN FRANCISCO, Calif., March 20 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc.today announced that patient treatment has commenced in a Phase II clinical trial of SNS-595, the company's lead anti-cancer therapeutic, in patients with small cell lung cancer. The trial is an open-label, multi-center study designed to examine the safety and
efficacy of SNS-595 as a second-line agent in patients with small cell lung cancer who have failed first-line therapy. SNS-595 is a first-in-class cell-cycle modulator that (in vitro) kills proliferating cancer cells by inducing apoptosis, or programmed cell death, as cells progress through the S
phase of the cell cycle.
"Sunesis continues to demonstrate rapid progress in the advancement of multiple oncology products through development. This Phase II study in small cell lung cancer -- our second Phase II trial for SNS-595 -- is the fourth clinical trial we have initiated since last fall," said Daniel N. Swisher,
President and Chief Executive Officer at Sunesis. "Through these studies, we are learning more about the promising anticancer activity of our two lead oncology candidates."
"Small cell lung cancer makes up approximately sixteen percent of lung cancers, and is characterized by rapid growth and spread, and commonly relapses within months of treatment," said Daniel Adelman, M.D., Senior Vice President of Research and Development at Sunesis. "First-line treatment for
small cell lung cancer typically involves use of a platinum drug such as cisplatin in combination with a second agent, typically etoposide. While these chemotherapies are beneficial, most patients' disease recurs. We believe that SNS-595 has the potential to provide a meaningful benefit in
second-line treatment as we have observed evidence of SNS-595's activity in platinum-resistant and etoposide-resistant xenograft models."
Patients with small cell lung cancer who have failed first-line treatment will be enrolled at multiple centers in the United States and Canada. Eligible patients will receive SNS-595 every three weeks at a dose and schedule identified in Sunesis' Phase I study of SNS-595 in patients with advanced solid malignancies. The trial design anticipates enrolling
80 patients -- 40 that are refractory and 40 that are sensitive.
According to the American Cancer Society, in 2006, approximately 160,000 people will die of lung cancer and approximately 174,000 new cases will be diagnosed in the U.S. alone. Of these, approximately sixteen percent will be
small cell lung cancer. Small cell lung cancer is estimated to affect approximately 34,000 patients in the U.S. alone with 29,000 new cases diagnosed each year. Characterized by the small round cells that make up small cell lung cancer tumors, this form of lung cancer tends to spread widely through the body as cells multiply quickly, forming large tumors and spreading to the lymph nodes and other organs. Small cell lung cancer is almost always associated with smoking.
About SNS-595
SNS-595 is a first-in-class cytotoxic with a novel mechanism of action. SNS-595 acts during the S phase of the cell cycle to induce rapid apoptosis of cells that are actively synthesizing DNA. Sunesis is currently conducting an open-label Phase II clinical study of SNS-595 in patients with non-small cell
lung cancer and a Phase I dose escalation safety clinical study in patients with acute leukemias. In clinical trials conducted to date, SNS-595 has been well tolerated and has shown promising signs of clinical activity. In addition, SNS-595 has exhibited broad activity in xenograft studies and
drug-resistant tumor models.
SOURCE Sunesis Pharmaceuticals, Inc.
investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc.,
+1-650-266-3717; or media, Karen L. Bergman, +1-650-575-1509, or Michelle
Corral, +1-415-794-8662, both of BCC Partners, for Sunesis Pharmaceuticals,
Inc.
20Mar06 13:30 GMT
Symbols:
us;SNSS
Source PRN PR Newswire
Categories:
GPGI - OTC Global Platinum + Gold, Inc. Announces Sale of Land for $3.2 Million
SALT LAKE CITY, March 20 /PRNewswire-FirstCall/ -- The following is being issued by Global Platinum + Gold, Inc. (OTC: GPGI):
Global is pleased to report that it has completed the sale of
approximately 200 acres of its 307-acre property near Coolidge, Arizona, for $3.2 million. This transaction provides Global with the funding capital necessary to construct its plant on the remaining acreage. Management has already met with contractors and engineering firms to obtain turnkey bids for
permits, architects renderings, buildings and equipment. It is estimated the plant can be constructed and be fully operational in approximately 120 days.
During the construction period Global's research and development department will finalize any new additions to the gold recovery process. Global also intends to complete the research needed to recover other platinum group metals. Global plans to add a line for the recovery of the platinum
group metals when the plant is completed.
Global hopes to commence limited commercial production at its existing facilities during the construction period. Based on our earlier pilot plant recoveries, this could be equal to 10 to 20 ounces of gold per week. Due to the large capital cost involved in the process, until now, we have not had sufficient funding to operate at this large a scale. Since the process of
handling smaller batches at our pilot plant facility is ontrolled, we anticipate there should be no problems with the scaling up of the process.
The plant will consist of approximately 10,000 square feet of processing space with room for expansion. The new plant will be a state of the art facility; partially automated with a well equipped laboratory and an initial capacity to process 10,000 gallons of leach solution per day with an ultimate
goal of 50,000 gallons per day. Please note the Salt Lake City, UT office has been closed and a new corporate office will be located in the Phoenix, AZ area as soon as possible.
Keep checking the Global website for the new address and phone numbers.
The Management team of Global is very excited about the future prospects of the Company and thanks you for your continued support.
SOURCE Global Platinum + Gold, Inc.
Robert J. Nielson of Global Platinum + Gold, Inc., +1-801-573-4131,
nielsonrj@aol.com
20Mar06 14:27 GMT
Symbols:
us;GPGI
Source PRN PR Newswire
Broadwing - BWNG.otc
UPDATE 2-Dutch investor boosts stake in Broadwing -- SEC
(Recasts, adds options comment, updates share price, changes
dateline from WASHINGTON)
CHICAGO, March 20 (Reuters) - Shares of Broadwing Corp.
<BWNG.O> rose 16 percent and options trading priced in more
gains on Monday tied to speculation that a Dutch media investor
may have takeover interest in the optical network operator,
several option analysts said on Monday.
Broadwing shares closed up $2.08, or 16.38 percent, at
$14.78 on Nasdaq on news that media mogul John de Mol now owns
a 5.03 percent stake in Broadwing. The news came in a document
filed with the U.S. Securities and Exchange Commission.
A representative for Broadwing was not immediately
available to comment on the stock and options activity.
"There is speculation that Dutch media mogul John De Mol
could lead a group or on his own make a bid for this company,"
said William Lefkowitz, an options strategist at brokerage firm
vFinance Investments.
De Mol told the SEC he acquired shares in Broadwing at
between $6.99 per share and $12.65 per share during a 60-day
period ending on March 8.
The 5.03 percent ownership calculation was based on 76.17
million ordinary shares of Broadwing outstanding as of Feb. 28,
according to the filing.
The document was jointly filed with the SEC on Friday by de
Mol and his investment firms, Talpa Beheer BV and Talpa Capital
BV. De Mol owns the Netherlands TV channel Talpa.
MORE CONSOLIDATION?
"Broadwing has been a vague takeover rumor of sorts ever
since the BellSouth takeover," wrote Larry McMillan of McMillan
Analysis Corp in a note to clients on Monday. "Stock volume
patterns are positive."
AT&T Inc. <T.N> agreed early this month to buy BellSouth
Corp. <BLS.N> for $65 billion, a deal that set off a raft of
speculation about additional consolidation in the
telecommunications industry.
Call options on Broadwing were active on Monday, indicating
that some investors were positioning for further strength in
the stock.
A total of 7,250 calls and 2,567 puts changed hands in the
U.S. options market in Broadwing on Monday, according to market
research firm Track Data.
Among the busiest were the call contracts that give the
right to buy Broadwing at $15 a share by mid-April. More than
1,700 April 15 calls traded on Monday. Those calls on the
Chicago Board Options Exchange cost $1.25, up 90 cents from
Friday.
(Additional reporting by Sinead Carew in New York, Julie
Vorman in Washington)
(20Mar06 22:33 GMT
Symbols:
ch;BLS de;BLS de;CIB de;CIBF gb;BSC nl;BLS us;BLS us;BWNG us;T us;VBL
Source RTRS Reuters News
Categories:
ABAX - Nasdaq, Abaxis Announces Licensing of Lyophilization Technology to bioMerieux
UNION CITY, Calif., March 21 /PRNewswire-FirstCall/ -- Abaxis, Inc.
(Nasdaq: ABAX), a medical products company manufacturing point-of-care blood
analysis systems, announced today that it has completed an agreement to
license a portion of its patent portfolio covering lyophilization technology
to bioMerieux SA.
"Our Orbos lyophilization technology, through the freeze drying of
reagents in small quantities, enables efficient manufacturing of reagents in a
convenient and stable format. This license with bioMerieux once again shows
that our Orbos technology is quickly becoming a standard format for reagent
utilization in molecular diagnostics," said Kenneth Aron, Ph.D.,
Vice-President of R&D at Abaxis.
"We now have several major companies utilizing our Orbos lyophilization
technology. All of these companies have recognized the utility of our
freeze-drying solution and are committed to utilizing our technology in a
number of their product lines."
Dr. Aron continued, "We see significant opportunities for further
licensing in the fields of molecular diagnostics and environmental monitoring.
These licensing opportunities are particularly attractive to Abaxis since
these fields are complementary to our own but in no way compete with our core
business of clinical chemistry. Since we get additional recurring revenue for
Abaxis, these licenses all represent classic win-win scenarios for us and for
our present and future licensees."
Abaxis does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
Contact: Clint Severson Lytham Partners, LLC
Chief Executive Officer Joe Dorame, Robert Blum, Joe Diaz
Abaxis, Inc. 602-889-9700
510-675-6500
SOURCE Abaxis, Inc.
Clint Severson, Chief Executive Officer of Abaxis, Inc., +1-510-675-6500; or
Joe Dorame, or Robert Blum, or Joe Diaz, all of Lytham Partners, LLC,
+1-602-889-9700, for Abaxis, Inc.
21Mar06 11:30 GMT
Symbols:
us;ABAX
Source PRN PR Newswire
Categories:
OTC Picks these stocks with good recent pps curves.
VSPC
ONTV
SPZI
SPRX
SVMI
HBSC
UCPJ
BSLM
NNVC
DMOI
DGKO
ARGY
TVEN
Only 100k moved through SURE today but hey if you are investing less than 5k in each than why worry?
Combined 6 month and 5 year chart stocks surprisingly are not proving as "stable" as I had hoped this week and last. Well stick with them and plow through to Friday though too confusing otherwise.
IS SURE at a top??.... how would you know that ???
SPRX added to MDG List Method 2, and Method 3 at $1.50.
SURE is a top, so it is removed from the MDG lists.
MDG list METHOD 2 up 70% down 30% for a nice day.
SURE posting a 400% increase from yesterdays close.
SURE 445% gain today, ice on the forehead for that one.
MDG Method 1 - up 17.3% down 47% or down 30/11 or 2.7%
MDG Method 2 - up 394% down 10% or up 384/10 or 38.4%
MDG Method 3 - up 322.55 / 9 or up 36%
Results: List redesign pays off, with the volatiles saving
the day with SURE posting a 377.3% increase.
BDGR forming a cup ? looks like a bottom anyways.
SPZI incredibly smooth weekly chart ( anti-stress) with a 50% gain today and approaching a 400% gain for the week.
CRGO finally coming off a bottom ? hard to say for sure.
SPRX, and DMOI nice gains today but not very intraday tradable curves as of note.
SURE, Cant say enough about this STORY stock today, up 100% from previous close, very tradable curve today, and 3 times normal volume